4-HO-DSBT

4-HO-DSBT: A Deep Dive into Its Serotonergic Mechanism[edit]

4-HO-DSBT or 4-hydroxy-N,N-di-sec-butyltryptamine, is a compound that belongs to the expansive tryptamine class. These compounds are renowned for their interactions with serotonin receptors, often resulting in varying degrees of psychoactive effects.

Historical Overview[edit]

The origins of 4-HO-DSBT can be traced back to the pioneering work of Dr. Alexander Shulgin. While Shulgin was the first to synthesize the compound, it is noteworthy that he did not carry out any tests on it^[1]. His documentation in the renowned book "TiHKAL" (Tryptamines I Have Known And Loved) provides an archival insight into its synthesis.

Pharmacological Profile[edit]

Serotonin Receptor Agonism: 4-HO-DSBT acts primarily as an agonist at the serotonin receptors. Agonism at these receptors is indicative of the compound's potential to produce psychoactive effects, given the central role of serotonin in mood regulation and perception.

Comparison with Isomers: Subsequent in vitro studies have differentiated 4-HO-DSBT from its n-butyl and isobutyl isomers. The s-butyl derivative (i.e., 4-HO-DSBT) was found to have a higher potency than its counterparts^[2].

5-HT2A Receptor Affinity: The 5-HT2A receptor affinity of 4-HO-DSBT is akin to that of MiPT, positioning it as a potent compound in the serotonergic agonism spectrum^[3].

Selectivity over 5-HT1A and 5-HT2B: One of the distinguishing features of 4-HO-DSBT is its heightened selectivity for the 5-HT2A receptor over the 5-HT1A and 5-HT2B subtypes. Such selectivity offers potential advantages in minimizing off-target effects and highlights its unique pharmacodynamic profile^[4].

Implications for Research and Medicine[edit]

Given its distinctive serotonergic profile, 4-HO-DSBT holds promise as a molecular tool for studying the serotonin system. Understanding its mechanism can provide insights into mood disorders, cognition, and perception. Further research into its safety profile, pharmacokinetics, and potential therapeutic applications is essential.

Conclusion[edit]

4-HO-DSBT, an intricate compound synthesized by Dr. Alexander Shulgin, offers a fascinating glimpse into the world of tryptamines and their interactions with the serotonin system. As researchers delve deeper into its pharmacological properties, the compound might pave the way for novel therapeutic avenues and a deeper understanding of serotonergic signaling.

References[edit]

↑ Shulgin, A., & Shulgin, A. (1997). TiHKAL: The Continuation. Transform Press.
↑ Nichols, D. E. (2004). Hallucinogens. Pharmacology & Therapeutics, 101(2), 131-181.
↑ Ray, T. S. (2010). Psychedelics and the human receptorome. PLoS One, 5(2), e9019.
↑ Halberstadt, A. L., & Geyer, M. A. (2011). Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology, 61(3), 364-381.

This article is a stub related to pharmacology. You can help WikiMD by expanding it!

Navigation-> Medicine - Wellness - Encyclopedia - Health topics - Diseases - Drugs - Gray's Anatomy - W8MD diet - Ketogenic diet - Recipes

Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Translate page: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian

[tihkal-1] Shulgin, A., & Shulgin, A. (1997). TiHKAL: The Continuation. Transform Press.

[research1-2] Nichols, D. E. (2004). Hallucinogens. Pharmacology & Therapeutics, 101(2), 131-181.

[research2-3] Ray, T. S. (2010). Psychedelics and the human receptorome. PLoS One, 5(2), e9019.

[selectivity3-4] Halberstadt, A. L., & Geyer, M. A. (2011). Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology, 61(3), 364-381.

[1]

[2]

[3]

[4]